

# CITATION REPORT

List of articles citing

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial

DOI: 10.1093/annonc/mdr045  
Annals of Oncology, 2012, 23, 200-205.

**Source:** <https://exaly.com/paper-pdf/52557868/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
154	Oxaliplatin-induced neuropathy in colorectal cancer. <b>2011</b> , 2011, 201593		51
153	Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. <b>2012</b> , 30, 3687-96		177
152	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. <b>2012</b> , 23, 739-44		13
151	Interaction between serotonin reuptake inhibitors, 5-HT <sub>3</sub> antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 2235-9	3.9	8
150	[Treatment of metastatic colorectal cancer: an illustration of the changes in the cancer paradigms]. <b>2012</b> , 41, 46-50		2
149	Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. <b>2012</b> , 29, 2793-9		30
148	Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion. <b>2012</b> , 29, 3592-3		5
147	Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 1313-9	3.9	46
146	Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. <b>2013</b> , 72, 305-14		26
145	Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. <b>2013</b> , 72, 1283-90		75
144	The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. <b>2013</b> , 9, 25-33		79
143	Neuropathic pain: treatment guidelines and updates. <b>2013</b> , 26, 580-7		28
142	Symptom assessment in elderly cancer patients receiving palliative care. <i>Annals of Oncology</i> , <b>2013</b> , 24 Suppl 7, vii25-29	10.3	6
141	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. <b>2013</b> , 63, 419-37		410
140	Reversible Bilateral Blepharoptosis following Oxaliplatin Infusion: A Case Report and Literature Review. <b>2013</b> , 99, e216-e219		1
139	Early and late long-term effects of adjuvant chemotherapy. <b>2013</b> , 9-14		9
138	Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. <b>2014</b> , 48, 626-32		22

137	Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society - Part Two. <b>2014</b> , 48, 423-35		19
136	Chemotherapy-induced peripheral neuropathy in the adult. <b>2014</b> , 26, 634-41		12
135	A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. <i>Supportive Care in Cancer</i> , <b>2014</b> , 22, 1807-14	3.9	72
134	Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. <i>Supportive Care in Cancer</i> , <b>2014</b> , 22, 1579-84	3.9	21
133	North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. <b>2014</b> , 120, 1890-7		56
132	Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain. <b>2014</b> , 10, 694-707		175
131	Prevention and treatment of chemotherapy-induced peripheral neuropathy. <b>2014</b> , 71, 19-25		59
130	Therapeutic strategies for cancer treatment related peripheral neuropathies. <b>2014</b> , 15, 567-80		22
129	Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements. <b>2014</b> , 30, 1895-908		14
128	Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). <b>2014</b> , 32, 997-1005		156
127	Occupational exposure to municipal solid wastes and development of toxic neuropathies: possible role of nutrient supplementation, complementary and alternative medicines in chemoprevention. <b>2014</b> , 20, 643-53		2
126	Oxaliplatin Neurotoxicity. <b>2014</b> , 10, 303-312		9
125	Chemotherapy-induced peripheral neuropathy #197. <b>2014</b> , 17, 965-6		1
124	Pain in cancer survivors. <b>2014</b> , 32, 1739-47		174
123	Oxaliplatin induced-neuropathy in digestive tumors. <b>2014</b> , 89, 166-78		33
122	Management options for established chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , <b>2014</b> , 22, 2281-95	3.9	40
121	Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <b>2014</b> , 32, 1941-67		788
120	Antinociceptive effects of venlafaxine in a rat model of peripheral neuropathy: role of alpha2-adrenergic receptors. <b>2014</b> , 738, 230-6		27

119	Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. <b>2014</b> , 13, 73-80		35
118	Chemotherapy-induced neuropathy: A comprehensive survey. <b>2014</b> , 40, 872-82		268
117	Neuropathic cancer pain: What we are dealing with? How to manage it?. <b>2014</b> , 7, 599-618		23
116	Venlafaxine for neuropathic pain in adults. <b>2015</b> , CD011091		39
115	Milnacipran inhibits oxaliplatin-induced mechanical allodynia through spinal action in mice. <b>2015</b> , 38, 151-4		5
114	Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. <b>2015</b> , 37, e13-8		2
113	Therapeutic opportunities for targeting cold pain pathways. <b>2015</b> , 93, 125-40		29
112	Psychopharmacology in cancer. <b>2015</b> , 17, 529		34
111	Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 513-24	3.9	35
110	[Chemotherapy-induced neuropathy]. <b>2015</b> , 86, 156-60		3
109	Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives. <b>2015</b> , 14, 1269-82		23
108	Symptom management in the older adult: 2015 update. <b>2015</b> , 31, 155-75		3
107	Platinum-induced neurotoxicity and preventive strategies: past, present, and future. <b>2015</b> , 20, 411-32		151
106	Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats. <b>2015</b> , 130, 81-7		27
105	Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 943-51	3.9	66
104	Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis. <b>2016</b> , 20, 237-41		9
103	Medical management of chemotherapy-induced peripheral neuropathy: a concise review focusing on the past 5 years. <b>2016</b> , 1, 121-126		
102	Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. <b>2016</b> , 15, 37-46		23

101	Pain Syndromes Associated with Cancer Therapy. <b>2016</b> , 25-62		2
100	Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 2085-2091	3.9	19
99	MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1071-8	3.9	36
98	Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. <b>2017</b> , 17, 409-419		37
97	Chemotherapy-induced peripheral neuropathy: limitations in current prophylactic strategies and directions for future research. <b>2017</b> , 33, 981-984		9
96	Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement (Opera) for chemotherapy-induced peripheral neuropathy management, a prospective study. <b>2017</b> , 34, 46		23
95	Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (Ki) on analgesia. <b>2017</b> , 42, 513-517		10
94	Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment. <b>2017</b> , 39, 1104-1122		33
93	Pain in chemotherapy-induced peripheral neurotoxicity. <b>2017</b> , 22, 156-161		19
92	[Chemotherapy-induced peripheral neuropathy and neuropathic pain]. <b>2017</b> , 31, 413-425		
91	Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. <b>2017</b> , 17, 1045-1060		18
90	Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy. <b>2017</b> , 15, 77-87		20
89	Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. <b>2017</b> , 22, 1154-e105		37
88	Chemotherapieinduzierte periphere Neuropathie. <b>2017</b> , 18, 44-53		
87	Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer. <b>2017</b> , 2017, 6236714		3
86	Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. <b>2018</b> , 124, 2289-2298		77
85	Antidepressants for the treatment of depression in people with cancer. <b>2018</b> , 4, CD011006		37
84	Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer. <b>2018</b> , 108, 14-19		23

83	Neurotoxicity Related to Radiotherapy and Chemotherapy for Nonsmall Cell and Small Cell Lung Cancer. <b>2018</b> , 409-417.e2	
82	Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis. <b>2018</b> , 7, 105-119	29
81	Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmagafodipir (PledOx): a placebo-controlled randomised phase II study (PLIANT). <b>2018</b> , 57, 393-402	52
80	SEOM clinical guideline for treatment of cancer pain (2017). <b>2018</b> , 20, 97-107	34
79	Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors. <b>2018</b> , 108, 508-516	0
78	Living Through Ovarian Cancer Treatment: Acute and Long-Term Toxicities of Chemotherapy for Advanced-Stage Disease. <b>2018</b> , 32, 1073-1085	2
77	Cancer Survivor Health Needs for Women. <b>2018</b> , 45, 659-676	0
76	Cancer Pain. <b>2018</b> , 17-35	
75	Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. <b>2018</b> , 33, 1675-1683	23
74	Prophylaxe und Therapie der chemotherapieinduzierten Polyneuropathie. <b>2018</b> , 13, 214-225	1
73	Cancer Pain. <b>2019</b> , 177-210	1
72	The Analgesic Effect of Venlafaxine and Its Mechanism on Oxaliplatin-Induced Neuropathic Pain in Mice. <b>2019</b> , 20,	10
71	Distinguishing analgesic drugs from non-analgesic drugs based on brain activation in macaques with oxaliplatin-induced neuropathic pain. <b>2019</b> , 149, 204-211	3
70	Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study. <b>2019</b> , 160, 1835-1846	18
69	Pain in Cancer of the Central Nervous System. <b>2019</b> , 153-160	
68	Protective Role of Epigallocatechin Gallate in a Rat Model of Cisplatin-Induced Cerebral Inflammation and Oxidative Damage: Impact of Modulating NF- $\kappa$ B and Nrf2. <b>2020</b> , 37, 380-396	18
67	Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis. <b>2020</b> , 99, e18653	9
66	Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1306-1319	10,3 62

65	Is there scientific evidence for the use of venlafaxine to treat neuropathic pain?. <b>2020</b> , 35, 522-530		
64	Pharmacotherapy for Small Fiber Neuropathy. <b>2020</b> , 22, 1		
63	Meta-analysis and P-curve analysis of the efficacy of venlafaxine versus placebo in the treatment of neuropathic pain. <b>2020</b> , 35, 597-598		
62	Chemotherapy-Induced Peripheral Neuropathy: Nursing Implications. <b>2020</b> , 43, 155-166		2
61	Chemotherapy-Induced Peripheral Neuropathy: Causative Agents, Preventative Strategies, and Treatment Approaches. <b>2020</b> , 34, 141-152		4
60	Guideline "diagnosis and non interventional therapy of neuropathic pain" of the German Society of Neurology (deutsche Gesellschaft für Neurologie). <b>2020</b> , 2, 16		14
59	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <b>2020</b> , 95, 672-690		11
58	Is there scientific evidence for the use of venlafaxine to treat neuropathic pain?. <b>2020</b> , 35, 522-530		0
57	S2k-Leitlinie: Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen. <b>2020</b> , 3, 21-40		11
56	Meta-analysis and P-curve analysis of the efficacy of venlafaxine versus placebo in the treatment of neuropathic pain. <b>2020</b> , 35, 597-598		
55	Drug Repositioning for the Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Mechanism- and Screening-Based Strategy. <b>2020</b> , 11, 607780		13
54	Non-opioid Analgesics and Emerging Therapies. <i>Cancer Treatment and Research</i> , <b>2021</b> , 182, 125-142	3.5	
53	Chemotherapy Toxicities. <b>2021</b> , 637-661		
52	Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 4223-4238	3.9	9
51	Capsaicin 8% patch Qutenza and other current treatments for neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN). <i>Current Opinion in Supportive and Palliative Care</i> , <b>2021</b> , 15, 125-131	2.6	4
50	An Overview of Chemotherapy-Induced Peripheral Neuropathy Resulting from Regimens Used in Gynecologic Malignancies. <i>Indian Journal of Gynecologic Oncology</i> , <b>2021</b> , 19, 1	0.2	
49	Preventive Efficacy and Safety of Yiqi-Wenjing-Fang Granules on Oxaliplatin-Induced Peripheral Neuropathy: A Protocol for a Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2021</b> , 2021, 5551568	2.3	
48	Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. <i>Seminars in Oncology</i> , <b>2021</b> , 48, 193-207	5.5	5

47	Approach to chemotherapy-induced peripheral neuropathy. <b>2021</b> , 356-370		
46	Symptoms and Symptom Management in Survivorship Patients. <b>2021</b> , 145-202		0
45	Management of Peripheral Neuropathy Induced by Chemotherapy. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 4698-4708	4.3	16
44	Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. <i>Current Neuropharmacology</i> , <b>2019</b> , 17, 184-196	7.6	49
43	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8474-88	5.6	8
42	Neuropathic cancer pain: prevalence, pathophysiology, and management. <i>Korean Journal of Internal Medicine</i> , <b>2018</b> , 33, 1058-1069	2.5	32
41	Pregabalin in Chemotherapy Induced Neuropathic Pain. <i>Indian Journal of Palliative Care</i> , <b>2016</b> , 22, 101-3	1.3	12
40	Characterization of Internal Validity Threats to Phase III Clinical Trials for Chemotherapy-Induced Peripheral Neuropathy Management: A Systematic Review. <i>Asia-Pacific Journal of Oncology Nursing</i> , <b>2019</b> , 6, 318-332	2.2	4
39	Antidepressant therapy in patients with cancer: A clinical review. <i>Taiwanese Journal of Psychiatry</i> , <b>2019</b> , 33, 13	0.4	4
38	Effects of analgesic on oxaliplatin-induced neurotoxicity in patients with gastrointestinal cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2015</b> , 16, 4465-8	1.7	7
37	Pharmacological Treatment of Established Chemotherapy-Induced Peripheral Neuropathy. <b>2021</b> , 155-181		0
36	Natural History of Chemotherapy-Induced Peripheral Neuropathy. <b>2021</b> , 1-18		
35	Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 331	12.8	3
34	Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. <i>Oncology and Therapy</i> , <b>2021</b> , 9, 385-450	2.7	13
33	Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment. <b>2013</b> , 139-161		
32	Treatment of Somatoform Disorders and Other Somatic Symptom Conditions (Pain, Fatigue, Hot Flashes, and Pruritus). <b>2014</b> , 163-187		
31	Therapy of Cancer-Related Pain and Cancer Therapy-Related Pain. <b>2015</b> , 59-78		
30	Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy. <i>Mental Health Clinician</i> , <b>2015</b> , 5, 289-295	1.6	0



29	Pharmacological Approaches and Natural Products for Prevention of Chemotherapy-Induced Peripheral Neuropathy - A Review. <i>International Journal of Pharmacology Phytochemistry and Ethnomedicine</i> , 6, 47-53		1
28	CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHES. <i>Meditinskiy Sovet</i> , 2017, 67-76	0.4	2
27	Gastrointestinal Cancer: Selection of Clinically Relevant Drug-Induced Toxicities Encountered in Gastrointestinal Cancer Treatment. 2018, 105-119		1
26	Neuromuscular Disease and Spinal Cord Compression. 2018, 543-561		
25	Place des psychotropes en oncologie. <i>Psycho-oncologie</i> , 2018, 12, 114-130	0	
24	Vybran'kapitoly z oštváatelstvŭ onkologii.		0
23	Chapitre 21. Les symptômes. 2020, 411-562		
22	Les autres symptômes. 2014, 290-373		
21	Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 10781552211052646	1.7	1
20	Chemotherapie-induzierte Polyneuropathien bleiben herausfordernd. <i>Im Focus Onkologie</i> , 2020, 23, 68-72		
19	Preventive effect of central administration of venlafaxine on morphine physical dependence, nociception, and blood cortisol level in rat. <i>International Journal of Preventive Medicine</i> , 2014, 5, 1422-31 <sup>1.6</sup>		9
18	Venlafaxine Attenuates Heat Hyperalgesia Independent of Adenosine or Opioid System in a Rat Model of Peripheral Neuropathy. <i>Iranian Journal of Pharmaceutical Research</i> , 2015, 14, 843-50	1.1	8
17	Vincristine-induced peripheral neuropathy in pediatric cancer patients. <i>American Journal of Cancer Research</i> , 2016, 6, 2416-2430	4.4	42
16	Nutraceuticals for Prevention of Chemotherapy-Induced Peripheral Neuropathy. 2022, 1222-1244		
15	Chemotherapeutics That Impair Microtubule Function: Axonopathy and Peripheral Neuropathies. 2022, 125-142		
14	Pharmacologic Management of Persistent Pain in Cancer Survivors.. <i>Drugs</i> , 2022, 82, 275	12.1	2
13	Activity dependent inhibition of TRPC1/4/5 channels by duloxetine involves voltage sensor-like domain. <i>Biomedicine and Pharmacotherapy</i> , 2022, 152, 113262	7.5	
12	Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity. 2022, 95-140		0

- 11 Correlation of stress and depression with cancer initiation and progression; a mechanistic review. **2022**, 23, ○
- 10 Chemotherapy-Induced Peripheral Neuropathy. **2022**, ○
- 9 Boswellia serrata. **2023**, 31-40 ○
- 8 Persistent chronic pain in cancer survivors: An update and future directions. **2022**, 6, 59 ○
- 7 Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. **2022**, 21, 1341-1355 ○
- 6 The involvement of the noradrenergic system in the antinociceptive effect of cucurbitacin D on mice with paclitaxel-induced neuropathic pain. 13, ○
- 5 Effect of melatonin on oxaliplatin induced neuropathy in patients receiving FOLFOX and XELOX chemotherapy regimens for stage II-IV colorectal cancer; A randomized, placebo controlled, double blind trial. ○
- 4 Red Ginger Extract Prevents the Development of Oxaliplatin-Induced Neuropathic Pain by Inhibiting the Spinal Noradrenergic System in Mice. **2023**, 11, 432 ○
- 3 PeptidePlatinum(IV) Conjugation Minimizes the Negative Impact of Current Anticancer Chemotherapy on Nonmalignant Cells. **2023**, 66, 3348-3355 ○
- 2 Antidepressants for the treatment of depression in people with cancer. **2023**, 2023, ○
- 1 Diabetische Neuropathie und diabetischer Fuß(Update 2023). **2023**, 135, 164-181 ○